Literature DB >> 31449793

FGF2-induced STAT3 activation regulates pathologic neovascularization.

Zhenyu Dong1, Andrea Santeford1, Norimitsu Ban1, Tae Jun Lee1, Craig Smith2, David M Ornitz3, Rajendra S Apte4.   

Abstract

Cell-autonomous endothelial cell (EC) fibroblast growth factor receptor (FGFR) signaling through FGFR1/2 is essential for injury-induced wound vascularization and pathologic neovascularization as in blinding eye diseases such as age-related macular degeneration. Which FGF ligand(s) is critical in regulating angiogenesis is unknown. Utilizing ex vivo models of choroidal endothelial sprouting and in vivo models of choroidal neovascularization (CNV), we demonstrate here that only FGF2 is the essential ligand. Though FGF-FGFR signaling can activate multiple intracellular signaling pathways, we show that FGF2 regulates pathogenic angiogenesis via STAT3 activation. The identification of FGF2 as a critical mediator in aberrant neovascularization provides a new opportunity for developing multi-target therapies in blinding eye diseases especially given the limitations of anti-VEGF monotherapy.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Choroid sprouting; Choroidal neovascularization; Endothelial cell; Fibroblast growth factor; Macular degeneration; Retina; STAT3

Mesh:

Substances:

Year:  2019        PMID: 31449793      PMCID: PMC6759401          DOI: 10.1016/j.exer.2019.107775

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  35 in total

1.  What Is Chronic or Persistent Diabetic Macular Edema and How Should It Be Treated?

Authors:  Rajendra S Apte
Journal:  JAMA Ophthalmol       Date:  2016-03       Impact factor: 7.389

2.  An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination.

Authors:  E N Meyers; M Lewandoski; G R Martin
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

3.  FGFR1 is independently required in both developing mid- and hindbrain for sustained response to isthmic signals.

Authors:  Ras Trokovic; Nina Trokovic; Sanna Hernesniemi; Ulla Pirvola; Daniela M Vogt Weisenhorn; Janet Rossant; Andrew P McMahon; Wolfgang Wurst; Juha Partanen
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

Review 4.  VEGF in Signaling and Disease: Beyond Discovery and Development.

Authors:  Rajendra S Apte; Daniel S Chen; Napoleone Ferrara
Journal:  Cell       Date:  2019-03-07       Impact factor: 41.582

5.  Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis.

Authors:  Sunday S Oladipupo; Craig Smith; Andrea Santeford; Changwon Park; Abdoulaye Sene; Luke A Wiley; Patrick Osei-Owusu; Joann Hsu; Nicole Zapata; Fang Liu; Rei Nakamura; Kory J Lavine; Kendall J Blumer; Kyunghee Choi; Rajendra S Apte; David M Ornitz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-19       Impact factor: 11.205

6.  GDF15 is elevated in mice following retinal ganglion cell death and in glaucoma patients.

Authors:  Norimitsu Ban; Carla J Siegfried; Jonathan B Lin; Ying-Bo Shui; Julia Sein; Wolfgang Pita-Thomas; Abdoulaye Sene; Andrea Santeford; Mae Gordon; Rachel Lamb; Zhenyu Dong; Shannon C Kelly; Valeria Cavalli; Jun Yoshino; Rajendra S Apte
Journal:  JCI Insight       Date:  2017-05-04

7.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Authors:  Nikhil Wagle; Caroline Emery; Michael F Berger; Matthew J Davis; Allison Sawyer; Panisa Pochanard; Sarah M Kehoe; Cory M Johannessen; Laura E Macconaill; William C Hahn; Matthew Meyerson; Levi A Garraway
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

8.  Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.

Authors:  J S Colvin; B A Bohne; G W Harding; D G McEwen; D M Ornitz
Journal:  Nat Genet       Date:  1996-04       Impact factor: 38.330

9.  Lung hypoplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme.

Authors:  J S Colvin; A C White; S J Pratt; D M Ornitz
Journal:  Development       Date:  2001-06       Impact factor: 6.868

10.  Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb induction.

Authors:  X Xu; M Weinstein; C Li; M Naski; R I Cohen; D M Ornitz; P Leder; C Deng
Journal:  Development       Date:  1998-02       Impact factor: 6.868

View more
  6 in total

1.  TPTEP1 suppresses high glucose-induced dysfunction in retinal vascular endothelial cells by interacting with STAT3 and targeting VEGFA.

Authors:  Xiaoping Sun; Yuebing Lu; Tao Lei
Journal:  Acta Diabetol       Date:  2021-02-12       Impact factor: 4.280

2.  Endothelial FGF signaling is protective in hypoxia-induced pulmonary hypertension.

Authors:  Kel Vin Woo; Isabel Y Shen; Carla J Weinheimer; Attila Kovacs; Jessica Nigro; Chieh-Yu Lin; Murali Chakinala; Derek E Byers; David M Ornitz
Journal:  J Clin Invest       Date:  2021-09-01       Impact factor: 14.808

3.  ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control.

Authors:  Joanna DeSalvo; Yuguang Ban; Luyuan Li; Xiaodian Sun; Zhijie Jiang; Darcy A Kerr; Mahsa Khanlari; Maria Boulina; Mario R Capecchi; Juha M Partanen; Lin Chen; Tadashi Kondo; David M Ornitz; Jonathan C Trent; Josiane E Eid
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

4.  A short deletion in the DNA-binding domain of STAT3 suppresses growth and progression of colon cancer cells.

Authors:  Yi-Jia Xiong; Dong-Yang Liu; Rong-Rong Shen; Yong Xiong
Journal:  Aging (Albany NY)       Date:  2021-02-01       Impact factor: 5.682

Review 5.  Key Role of Astrocytes in Postnatal Brain and Retinal Angiogenesis.

Authors:  Mariela Puebla; Pablo J Tapia; Hilda Espinoza
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

Review 6.  Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer.

Authors:  Yoshikazu Nakamura
Journal:  Cells       Date:  2021-06-28       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.